Nasdaq: VOGX · Listed Aug 12, 2026
Vogenx IPO
IPO price
$13.00
Vogenx (VOGX) priced its IPO at $13.00 a share and has traded on Nasdaq since Aug 12, 2026.
VOGX today$12.34-5.08%since IPO15-min delayed · as of 7:30:02 PM EST on Nov 18, 2026
See the VOGX quoteFirst trading day · Aug 12, 2026
- IPO price
- $13.00
- the top of the range of $11 to $13
- First trade
- $13.00
- +0.00% from the IPO price
- First-day last trade
- $13.04
- +0.31% from the IPO price, regular session
- Raise
- $81.25M
- before the underwriters' option
These numbers are from the first trading day, Aug 12, 2026.
How VOGX did against the market
VOGX against the market, from its first trade at 12:10 ET to the last trade of the session.
- VOGX from its first trade
- +0.31%
- Against the market (QQQ)
- +0.4 pts
VOGX rose 0.3% from its first trade to the last trade of the session. That is 0.4 points better than the market.
Same-day moves do not show that VOGX caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
VOGX against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
VOGX against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Vogenx '26 | $81.25M | +0.00% | +0.31% | +50.08% | +100.00% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Vogenx IPO offers 6.25M shares to raise $81.25M, before any underwriters' option.
- Expected price range
- $11 to $13
- IPO price
- $13.00
- Shares offered
- 6.25M
- Money raised
- $81.25M
- Listing date
- Aug 12, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Vogenx$81.25M
Where VOGX ranks
Vogenx's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- VOGX$183.31M
Filings and the company
What Vogenx has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Vogenx discloses to the SEC on Form 8-K.
- Quarterly earningsNov 6, 2026
On November 6, 2026, Vogenx, Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2026.
- Director departureOct 9, 2026
On October 7, 2026, concurrent with his becoming an employee of Vogenx, Inc. (the "Company") as Chief Commercial Officer, Richard Gorman resigned from the Board of Directors ("Board") of the Company and from all committees of the Board on which he served, including the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, effective October 12, 2026. Mr. Gorman's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Director appointmentSep 22, 2026
On September 21, 2026, the Board of Directors ("Board") of Vogenx, Inc. (the "Company") appointed Ken Toombs to the Board as a Class II director, to serve until the 2028 annual meeting of stockholders of the Company or until his successor is duly elected and qualified or until his earlier death, resignation or removal. The Board determined that Mr. Toombs qualifies as an "independent director" under the listing rules of the Nasdaq Stock Market and applicable rules and regulations of the Securities and Exchange Commission.
- Underwriting agreementAug 19, 2026
Under the terms of an underwriting agreement dated August 11, 2026 (the "Underwriting Agreement") by and between the Company and JonesTrading Institutional Services LLC (the "Underwriter"), the Company granted the Underwriter a 45-day option to purchase up to 937,500 additional shares of common stock at the public offering price of $13.00 (the "Over-Allotment Option").
- Charter amendmentAug 13, 2026
The Company filed a second amended and restated certificate of incorporation (the 'Amended and Restated Charter') with the Secretary of State of the State of Delaware. The Amended and Restated Charter amends and restates the Company's existing amended and restated certificate of incorporation, as amended, in its entirety to, among other things, (i) authorize 500,000,000 shares of common stock, par value $0.0001 per share; (ii) eliminate all references to the previously existing series of preferred stock; and (iii) authorize 10,000,000 shares of undesignated preferred stock, par value $0.0001 per share.
About Vogenx
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
- Ticker
- VOGX
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- PHARMACEUTICAL PREPARATIONS
- Employees
- 7
- Listed
- Aug 12, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the Vogenx IPO price?
$13.00 a share.
When did Vogenx go public?
Vogenx listed on Nasdaq on Aug 12, 2026 under the ticker VOGX.
How much did the Vogenx IPO raise?
$81.25M, before any underwriters' option.
How did Vogenx open on its first day?
VOGX first traded at $13.00, +0.00% from the IPO price of $13.00.
How did VOGX close on its first day?
Its last regular-session trade was $13.04, +0.31% from the IPO price of $13.00.
What was the VOGX first-day trading range?
$12.95 to $13.88 in the regular session.
How many VOGX shares traded on the first day?
667.55K shares in the regular session.
How many shares did Vogenx sell in its IPO?
6.25M shares.
How did VOGX do against the market on its first day?
VOGX rose 0.3% from its first trade to the last trade of the session. That is 0.4 points better than the market (QQQ, the Nasdaq-100 ETF).
What exchange is VOGX listed on?
Vogenx lists on Nasdaq under the ticker VOGX.
Build with Massive
Get the VOGX data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/VOGX/range/5/minute |
| Market cap | /v3/reference/tickers/VOGX |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.